Senti Biosciences (SNTI) Institutional Ownership → Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (From Priority Gold) (Ad) Free SNTI Stock Alerts $0.28 0.00 (-1.32%) (As of 02:00 PM ET) Add Compare Share Share OwnershipStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Institutional Ownership Changes (13F Filings) for Senti Biosciences (NASDAQ:SNTI)CurrentInstitutional OwnershipPercentage25.73%Number ofInstitutional Buyers(last 12 months)4TotalInstitutional Inflows(last 12 months)$1.94MNumber ofInstitutional Sellers(last 12 months)1TotalInstitutional Outflows(last 12 months)$44.93K Get SNTI Insider Trade Alerts Want to know when executives and insiders are buying or selling Senti Biosciences stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data SNTI Institutional Buying and Selling by Quarter Ad Priority GoldRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.Click here for your free guide Senti Biosciences Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails2/12/20248VC GP I LLC2,537,558$1.68M1.7%N/A5.697% 1/17/2024 ARK Investment Management LLC1,969,860$1.30M0.0%+7.9%4.423% 10/27/2023TD Asset Management Inc241,208$102K0.0%+88.4%0.542% 9/7/2023Triatomic Management LP300,533$188K0.2%+42.5%0.675% 7/10/2023 ARK Investment Management LLC1,829,815$1.15M0.0%-3.8%4.143% 5/3/2023Triatomic Management LP210,883$249K0.2%+39.0%0.477% 4/17/2023 ARK Investment Management LLC1,901,467$2.24M0.0%-1.3%4.305% 2/14/2023Triatomic Management LP151,675$214K0.2%+168.7%0.346% 2/13/2023Artal Group S.A.55,555$78K0.0%-94.7%0.127% 2/7/2023TD Asset Management Inc118,292$167K0.0%-12.3%0.270% 1/24/2023 ARK Investment Management LLC1,925,827$2.72M0.0%-7.8%4.391% 11/15/2022Triatomic Management LP56,454$123K0.1%N/A0.129% 11/7/2022TD Asset Management Inc.134,892$285K0.0%+53.8%0.308% 11/3/2022The Manufacturers Life Insurance Company117,707$248K0.0%N/A0.269% 10/17/2022 ARK Investment Management LLC2,087,696$4.53M0.0%N/A4.771% 8/11/2022Artal Group S.A.1,055,555$2.07M0.1%N/A4.450% 8/8/2022Allen Operations LLC21,443$42K0.0%N/A0.090% 8/4/2022TD Asset Management Inc.87,696$172K0.0%N/A0.370% 7/29/2022Kingfisher Capital LLC113,163$222K0.1%N/A0.477% (Data available from 1/1/2016 forward) SNTI Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of SNTI shares? During the previous two years, 9 institutional investors and hedge funds held shares of Senti Biosciences. The most heavily invested institutionals were 8VC GP I LLC ($1.68M), ARK Investment Management LLC ($1.30M), TD Asset Management Inc. ($285K), The Manufacturers Life Insurance Company ($248K), Kingfisher Capital LLC ($222K), Triatomic Management LP ($188K), and TD Asset Management Inc ($102K).Learn more on SNTI's institutional investors. What percentage of Senti Biosciences stock is owned by institutional investors? 25.73% of Senti Biosciences stock is owned by institutional investors. Learn more on SNTI's institutional investor holdings. Which institutional investors have been buying Senti Biosciences stock? Of the 9 institutional investors that purchased Senti Biosciences stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: 8VC GP I LLC ($2.54M), ARK Investment Management LLC ($2.23M), Artal Group S.A. ($1.06M), Triatomic Management LP ($300.53K), TD Asset Management Inc. ($134.89K), The Manufacturers Life Insurance Company ($117.71K), and TD Asset Management Inc ($113.17K). How much institutional buying is happening at Senti Biosciences? Institutional investors have bought a total of 6,625,504 shares in the last 24 months. This purchase volume represents approximately $9.60M in transactions. Which Senti Biosciences major shareholders have been selling company stock? The following institutional investors have sold Senti Biosciences stock in the last 24 months: Artal Group S.A. ($1M), ARK Investment Management LLC ($257.88K), and TD Asset Management Inc ($16.60K). How much institutional selling is happening at Senti Biosciences? Institutional investors have sold a total of 1,274,481 shares in the last 24 months. This volume of shares sold represents approximately $1.74M in transactions. Related Companies: Inhibikase Therapeutics Major Shareholders Coeptis Therapeutics Major Shareholders Genetic Technologies Major Shareholders Organovo Major Shareholders BioCardia Major Shareholders PharmaCyte Biotech Major Shareholders Surrozen Major Shareholders Aptose Biosciences Major Shareholders Creative Medical Technology Major Shareholders Evaxion Biotech A/S Major Shareholders This page (NASDAQ:SNTI) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarThe A.I. story nobody is telling you (Read ASAP)TradeSmithRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldHe Is Giving Away BitcoinCrypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyYour Money is Not SafeAmerican Alternative Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Senti Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
